BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
Phase 1
Completed
- Conditions
- Castration-Resistant Prostate CancerBone Metastases
- Interventions
- First Posted Date
- 2010-04-19
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 70
- Registration Number
- NCT01106352
Therapeutic Effectiveness of Vardenafil in Patients With Erectile Dysfunction and Metabolic Syndrome in Daily Clinical Practice
- First Posted Date
- 2010-04-19
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2289
- Registration Number
- NCT01106118
Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension
Phase 1
Completed
- Conditions
- Anti-Infective Agents
- Interventions
- First Posted Date
- 2010-04-16
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 26
- Registration Number
- NCT01105208
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2014-11-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 460
- Registration Number
- NCT01104584
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Phase 3
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2010-04-14
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 760
- Registration Number
- NCT01103323
Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients
Phase 4
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2010-04-05
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 151
- Registration Number
- NCT01098760
Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)
Completed
- Conditions
- Secondary PeritonitisAbscess, Intra-Abdominal
- Interventions
- First Posted Date
- 2010-03-31
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1001
- Registration Number
- NCT01096511
Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel
Phase 1
Completed
- Conditions
- ContraceptionContraception, Postcoital
- Interventions
- First Posted Date
- 2010-03-31
- Last Posted Date
- 2013-06-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 24
- Registration Number
- NCT01096485
Cross -Over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel
Phase 1
Completed
- Conditions
- ContraceptionContraception, Postcoital
- Interventions
- First Posted Date
- 2010-03-31
- Last Posted Date
- 2013-06-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 24
- Registration Number
- NCT01096498
Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors
- First Posted Date
- 2010-03-30
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 33
- Registration Number
- NCT01096030